Clonal Hematopoiesis: Updates and Implications at the Solid Tumor-Immune Interface.
Marco M ButtigiegMichael J RauhPublished in: JCO precision oncology (2023)
Recent larger-scale studies of patients with cancer and longitudinal population cohorts have revealed how age-related expansions of mutant hematopoietic cells (clonal hematopoiesis [CH]) have differential associations with incident and prevalent cancers and their outcomes. Increasing recognition and deeper understanding of genetic subtypes of CH are yielding insights into the tumor-immune interface that may help to explain the heterogeneous impact of CH on tumorigenesis and treatment. Herein, we update the expanding influence of CH in precision oncology and propose important research and clinical questions to address to effectively manage and harness CH in oncology patients.
Keyphrases
- room temperature
- palliative care
- newly diagnosed
- end stage renal disease
- induced apoptosis
- ejection fraction
- cardiovascular disease
- prognostic factors
- healthcare
- gene expression
- bone marrow
- endoplasmic reticulum stress
- adipose tissue
- type diabetes
- genome wide
- oxidative stress
- single cell
- signaling pathway
- patient reported
- young adults
- health insurance
- case control
- childhood cancer